Paper Details

  1. Home
  2. Paper Details

A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer.

Author: AmirE, ClemonsM, ColeD E C, DowsettM, DranitsarisG, FolkerdE, FreedmanO C, HannaW, KahnH, O'MalleyF, VermaS

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Aromatase inhibitors are drugs used to treat breast cancer. This study compared two types of aromatase inhibitors, exemestane (steroidal) and anastrozole (non-steroidal), in postmenopausal women. The researchers found that the order in which these drugs were used had little impact on outcomes. Most patients preferred anastrozole over exemestane, suggesting that patient preference should be considered in treatment decisions.
Paper Details　
Original Abstract of the Article :
Several adjuvant endocrine strategies exist for postmenopausal women with breast cancer. This study compared the effect of two sequences of aromatase inhibitor use [steroidal (exemestane) and non-steroidal (anastrozole)] on serological and pathological biomarkers when given in the neoadjuvant settin...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s10549-009-0523-x

データ提供：米国国立医学図書館（NLM）

A Randomized Trial Exploring the Biomarker Effects of Neoadjuvant Sequential Treatment with Exemestane and Anastrozole in Post-Menopausal Women with Hormone Receptor-Positive Breast Cancer

Breast cancer is a leading cause of cancer-related deaths in women. This research explores the effects of sequential treatment with two aromatase inhibitors, exemestane and anastrozole, in postmenopausal women with hormone receptor-positive breast cancer. The study utilized a randomized trial design to compare the effects of these two medications on various biomarkers, including serum hormone levels and tumor proliferation markers. The findings suggest that the order of administration of these two aromatase inhibitors has little impact on biomarker changes and clinical response, but patients may have personal preferences for one medication over the other.

Aromatase Inhibitors for Breast Cancer

This research provides insights into the use of aromatase inhibitors in the treatment of hormone receptor-positive breast cancer. The study found no significant differences in biomarker changes or clinical response between patients receiving exemestane followed by anastrozole versus the reverse sequence. However, the majority of patients expressed a preference for anastrozole, highlighting the importance of patient-centered care in treatment decisions.

Breast Cancer Treatment Options

This research offers valuable information for patients with hormone receptor-positive breast cancer, suggesting that both exemestane and anastrozole are effective treatment options. The study highlights the importance of discussing treatment options with healthcare providers, considering individual preferences and potential side effects to develop a personalized treatment plan.

Dr. Camel's Conclusion

Just like a camel navigates the desert, doctors need to carefully consider the various treatment options available for patients with breast cancer. This research suggests that while the order of aromatase inhibitor administration may not significantly impact outcomes, individual patient preferences should be considered. By providing patients with a clear understanding of their options and empowering them to make informed decisions, doctors can ensure that patients receive the most effective and personalized care.

Date :
  1. Date Completed 2010-02-22
  2. Date Revised 2022-01-29
Further Info :

Pubmed ID

19731013

DOI: Digital Object Identifier

10.1007/s10549-009-0523-x

Related Literature

Article Analysis
・Effects of exemestane
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.